Thoratec seeks go-ahead for Canadian trials:
This article was originally published in Clinica
Executive Summary
Thoratec Laboratories has submitted an application to the Canadian government to begin clinical trials of its prosthetic coronary artery bypass graft (CABG). The Aria CABG, which incorporates the company's proprietary biomaterial Thoralon, will initially be targeted at the 20% of all bypass patients who have few or no suitable native vessels. The 330-patient trial is expected to last one to two years following the completion of patient enrolment, said the Pleasanton, California-based company. It plans to seek approval to begin a US trial of the device later this year.